

Personal Information

**CARMELO RIZZARI**

 MBBM Foundation c/o Azienda Socio-Sanitaria Territoriale, Monza, Italy  
 0392336816 fax 039.2336826  
 c.rizzari@hsgerardo.org, carmelo.rizzari@gmail.com

Gender Male DOB 13/10/1958| Italy

Professional Skills

**9.4.84-9.10.85:** Medical Officer, Italian Military Navy  
**27.5.86-20.9.88:** Permanent Member of the 23rd Commission (ASL Catania) for the evaluation of Civil Invalidity  
**22.1.88-25.5.88:** Medical activity of substitution for General Practitioners or Pediatricians belonging to the Italian Health Service  
**7.7.88-15.9.88:** Medical Service in the public area of care continuity.  
**15.3.89-31.10.90:** Family Pediatrician (Cinisello Balsamo, Milano, Italy, USSL 66).  
**1.10.90 onwards:** Staff Member of the Pediatric Department of the University of Milano Bicocca, Hospital S. Gerardo of Monza with the following assignments and roles:  
**1.10.90-2.6.2002:** Staff Assistant Member  
**3.6.2002-15.6.2009:** Staff Associate Member - High Specialization  
**15.6.2009 onwards:** Head of the Pediatric Hematology-Oncology Unit at the Department of pediatrics, University of Milano Bicocca, MBBM Foundation c/o Azienda Socio-Sanitaria Territoriale, Monza., Italy

Personal competencies

Mother language Italiano

Other languages

	COMPREHENSION		SPOKEN		WRITTEN
	Listening	Reading	Interaction	Oral	
English	C1-C2	C1-C2	C1-C2	C1-C2	C1-C2
German	A1-A2	A1-A2	A1-A2	A1-A2	A1-A2

Levels : A1/A2: Basic - B1/B2: Intermediate - C1/C2: Advanced

Digital Competencies

AUTOEVALUATION

Levels : Basic - Intermediate - Advanced

Communication	Contents creation	Security	Problem Solving
Intermediate	Intermediate	Intermediate	Intermediate

Personal data

Authorize according to Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

## Professional skills

Involved since the late 80ies in the field of pediatric leukemias with special expertise developed in the field of cancer chemotherapy. Currently he is the full Responsible of the Pediatric Hematology-Oncology Unit in Monza, the largest and first recruiting center for hematological malignancies in Italy.

His main professional and scientific achievements are listed below:

- Participation in the development and drafting of the chemotherapy protocols adopted in Italy since the late 80ies by the AIEOP for the **first-line ALL protocols** (AIEOP LLA 91, 95, 2000 and the international AIEOP-BFM ALL 2009 wherein he has been a member of the Trial Steering Committee and has been appointed international study coordinator for the pharmacological studies conducted within this trial for E.Coli PEG-ASP and Erwinia C. Asparaginases).
- Participation in the development and drafting of the chemotherapy protocols adopted in Italy since the late 80ies by the AIEOP for the second-line ALL protocols (REC 98, REC 2003 - wherein he has served as co-PI since 2007 - and the international INTREALL SR funded under the FP7 project for the European Community -wherein he serves as national co-PI and as international coordinator of the european working group on studies for Asparaginase studies).
- Participation in the development and drafting of the chemotherapy protocols adopted in Italy since the late 90ies by the AIEOP for **the first-line** (AML AIEOP 2002/01-02, AIEOP LAM 2013) and second line (the international IBFMSG Relapsed AML 2002 and 2015 study) Acute Myeloid Leukemia (AML) protocols.
- Current member of the Trial Steering Committee of the ongoing international protocol AIEOP-BFM ALL 2017 for the first-line of ALL treatment.
- Member of the AIEOP Scientific Committees for 1. ALL 2. AML. 3. Myelodysplastic Syndromes 4. Histiocytoses.
- Since May 2012 chairman of the AIEOP Scientific Committee for Clinical Pharmacology and Pharmacovigilance.
- Member of the Trial Steering Committee for an upcoming european study for Relapsed AML I-BFM-SG AML Relapsed to be started in 2017.
- Member of the European Working Group for the design and implementation of a common european protocol for AML to be started in 2019.
- Italian Principal Investigator and member of the 'European Advisory Board of the international randomized EPO-INT-51 on the role of erythropoietin Alfa in the treatment of pediatric patients with acute lymphoblastic leukemia or solid tumors.
- Local Principal Investigator of several Phase I-II studies on Clofarabine (Amgen), Dasatinib (Bristol Myers Squibb) Forodesine (Mundipharma), Midostaurine (Novartis), Nilotinib (Novartis), Blinatumomab (Amgen), Bortezomib (Academic Trial), NI-0501-04

- (Novimmune), Volasertib (Boehringer Ingelheim), Azacytidine (Celgene), Inotuzumab Ozogamycin (Pfizer), Carfilzomib (Amgen), Bosutinib (Pfizer), Atezolizumab (Genentech).
- "Expert Consultant" independent outside of the "Therapeutic Expert Group" for the part relating to leukemias and lymphomas" within the project called "TEDDY" (acronym for Task-force in Europe for Drug Development for the Young) in the 90ies
  - From June 2010 to June 2013 member on behalf of the Italian centers, of the International Quality and Accreditation Committee of the european ITCC (Innovative Therapies in Children with Cancer) consortium and local coordinator for the center of Monza.
  - Enabled in 2013 to hold the position of associate professor in the national academic selection for the General and Specialistic areas of Pediatrics (MED38).
  - Author and coauthor of 94 peer reviewed publications in medium-high IF score journals (among whom Lancet, Lancet Oncology, Lancet Haematology, Journal Clinical Oncology, Blood, British Journal of Haematology, British Journal of Cancer, Cancer, Haematologica, Leukemia).
  - Author and coauthor of over 200 abstracts in several occasions accepted for poster or oral presentation in several national and international meetings such as AIEOP, ASH, ASPHO, SIOP.
  - Invited Speaker at several national and international meetings and Pediatric Hematology-Oncology and anticancer pharmacology.
  - Author of the following chapters in scientific books: "Asparaginase T of acute leukemias – new directions for clinical research", edited by New Jersey, 2002. "Le leucemie acute in età pediatrica" in Fondam Editors. F. Cavalli, F. Cognetti A. Costa, R. Orecchia, Elsevier Italia, 20
  - Chairman and speaker at several international scientific conferences ASH, SIOP, IBFMSG, ESH, SIE, SIES).
  - International Data Monitoring Committee Member and Chairman trials regarding supportive therapy agents in the field of pediatric l (PEG-Filgrastim-TEVA)
  - Member of the Data Monitoring Committee appointed by the F Committee (Chairman Prof A. Baruchel, Paris) for the currently o french protocol for childhood ALL CAALL F01.
  - Appointed scientific secretary of the AIEOP national Board 2002 Jankovic, Monza), member of the AIEOP national Board 2004-2006 (P Rome Bambino Gesù) and of the current AIEOP national Board 20 Fagioli, Torino).
  - Appointed as representative of the International BFM Study Group (I the Enpr-EMA Coordinating Group, governing body of the Europe Research at the European Medicines Agency, in March 2016. This pos renewed for a three-year term from January 2018.
  - Lecturer for students of the Medical School and for post-graduates at

of Specialization in Paediatrics

- Tutor, supervisor and co-rapporteur of several theses of the Medical Residency School in Pediatrics of the University of Milano Bicocca.
- Peer-reviewer for several high-scored scientific journals in the field (Haematologica, Cancer, Pediatric Blood and Cancer, Journal of Clinical Oncology, International Journal of Pediatric Hematology and Oncology, Lancet Oncology, Lancet Haematology).
- Active member of the following scientific societies/networks/consortia: SIOP, SIOP Europe.
- Certificate of ICH Good Clinical Practice E6 (R2) on October, 5, 2017
- Member since 2015 of the European EnPreMA network, sponsored by the Medicines Agency (EMA) in the context of projects to improve the use of drugs in the field of paediatrics by the European Community, representing the International BFM Study Group.
- In 2018 he was elected to the Board of SIOP Europe with the role of President of the Clinical Trials European groups.
- Enabled in 2019 to hold the position of full professor in the national area of General and Specialistic areas of Pediatrics (MED38).
- In January 2020 he has been elected President elect of the European Society for Pediatric Oncology (SIOPE)

Fiscal Code RZZCML58R13C351I

Data 29.01.2020

Signature

